<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04515394</url>
  </required_header>
  <id_info>
    <org_study_id>MS202202_0002</org_study_id>
    <secondary_id>2020-001776-15</secondary_id>
    <nct_id>NCT04515394</nct_id>
  </id_info>
  <brief_title>Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)</brief_title>
  <official_title>A Phase II Single-Arm Study to Investigate Tepotinib Combined With Cetuximab in RAS/BRAF Wild-Type Left-Sided mCRC Patients Having Acquired Resistance to Anti-EGFR Antibody Targeting Therapy Due to MET Amplification (PERSPECTIVE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono Research &amp; Development Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the preliminary antitumor activity, safety and&#xD;
      tolerability of tepotinib in combination with cetuximab in participants with RAS/BRAF&#xD;
      wild-type left-sided Metastatic Colorectal Cancer (mCRC) having acquired resistance to&#xD;
      anti-epidermal growth factor receptor (EGFR) antibody targeted therapy due to mesenchymal&#xD;
      epithelial transition (MET) amplification.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2021</start_date>
  <completion_date type="Anticipated">March 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 23, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing Dose Limiting Toxicities (DLTs) According to National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) for Adverse Events (AEs) Version 5.0</measure>
    <time_frame>Day 1 to Day 21 of Cycle 1 (each cycle is of 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1) Assessed by Investigators</measure>
    <time_frame>Time from first study treatment assessed up to 556 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1) Assessed by Investigators</measure>
    <time_frame>Time from first study treatment assessed up to 556 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1) Assessed by Investigators</measure>
    <time_frame>Time from first study treatment assessed up to 556 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Assessed by Investigators</measure>
    <time_frame>Time from first study treatment assessed up to 556 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) and Treatment Related Adverse Events (TRAEs)</measure>
    <time_frame>Time from first study treatment up to 30 days after the last dose, assessed up to 221 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Vital Signs, Laboratory Parameters and 12-lead Electrocardiogram (ECG) Findings</measure>
    <time_frame>Time from first study treatment up to 30 days after the last dose, assessed up to 221 days</time_frame>
    <description>Number of participants with clinically significant changes in vital signs, laboratory parameters and 12-lead ECG will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-Drug Antibodies (ADAs) for Cetuximab</measure>
    <time_frame>At Day 1 of cycle 1 (each cycle is of 21 days) and at End of Treatment (14 days after last dose, assessed up to 205 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Tepotinib + Cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tepotinib</intervention_name>
    <description>Participants will receive Tepotinib initially at 500 milligrams (mg) once daily (QD) (2 film coated tablets of 250 mg QD). For potential dose de-escalation, the available 250 mg dose strength will be used (1 tablet once daily) until disease progression (according to Response Evaluation Criteria in Solid Tumors Version 1.1 [RECIST v1.1]), death, Adverse event (AE) leading to discontinuation, study withdrawal, or withdrawal of consent, whichever occurs first.</description>
    <arm_group_label>Tepotinib + Cetuximab</arm_group_label>
    <other_name>MSC2156119J</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab, is administered at an initial dose of 400 milligrams per square meter (mg/m^2) body surface area, over a recommended intravenous infusion period of 120 minutes and a maximum infusion rate of 5 milligrams per minute (5 mg/min), followed by or starting with weekly infusions at a dose of 250 mg/m^2 over a recommended infusion period of 60 minutes and a maximum infusion rate of 10 mg/min until disease progression, death, Adverse event (AE) leading to discontinuation of both study interventions, study withdrawal, or withdrawal of consent, whichever occurs first.</description>
    <arm_group_label>Tepotinib + Cetuximab</arm_group_label>
    <other_name>ErbituxÂ®</other_name>
    <other_name>MSB0010442D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Advanced (locally advanced or metastatic) left sided (from splenic flexure to rectum -&#xD;
             National Comprehensive Cancer Network [NCCN] version 4.2020) colorectal cancer (CRC)&#xD;
             with RAS/BRAF wild-type at study entry confirmed prior to enrollment, with previous&#xD;
             anti-epidermal growth factor receptor (anti-EGFR) therapy and acquired resistance on&#xD;
             the most recent anti-EGFR monoclonal antibody therapy (panitumumab or cetuximab) by&#xD;
             radiological documentation of disease progression according to RECIST Version 1.1&#xD;
&#xD;
          -  Mesenchymal epithelial transition (MET) amplification detected by a positive liquid&#xD;
             biopsy and/or tissue with appropriate regulatory status (collected after disease&#xD;
             progression of the previous anti-EGFR therapy)&#xD;
&#xD;
          -  Measurable disease by Investigator in accordance with RECIST Version 1.1&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1&#xD;
&#xD;
          -  Life expectancy greater than 3 months&#xD;
&#xD;
          -  Participants having at least one systemic treatment for mCRC including 1 anti-EGFR&#xD;
             monoclonal antibody therapy as the most recent line of therapy for mCRC before study&#xD;
             treatment and must have shown a radiologically confirmed by RECIST Version 1.1&#xD;
             complete response (CR) or partial response (PR), both for at least 4 months or stable&#xD;
             disease (SD) for at least 6 months to that therapy prior to disease progression&#xD;
&#xD;
          -  Less than 2 months between the last administration of the most recent EGFR containing&#xD;
             regimen and first dosing in this study&#xD;
&#xD;
          -  Adequate hematological function, hepatic and renal functions as defined in the&#xD;
             protocol&#xD;
&#xD;
          -  Signed and dated informed consent indicating that the participants had been informed&#xD;
             of all the pertinent aspects of the trial prior to enrollment&#xD;
&#xD;
          -  Contraceptive use by males or females will be consistent with local regulations on&#xD;
             contraception methods for those participating in clinical studies&#xD;
&#xD;
          -  Other protocol defined inclusion criteria could apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with symptomatic central nervous system (CNS) metastases who are&#xD;
             neurologically unstable or have required increasing doses of steroids within the 2&#xD;
             weeks prior to study entry to manage CNS metastases. Also excluded are participants&#xD;
             with carcinomatous meningitis&#xD;
&#xD;
          -  Participants who have brain metastasis as the only measurable lesion&#xD;
&#xD;
          -  Prior chemotherapy, biological therapy, radiation therapy, hormonal therapy for&#xD;
             anti-cancer purposes, targeted therapy, or other investigational anticancer therapy&#xD;
             (not including palliative radiotherapy at focal sites) within 21 days prior to the&#xD;
             first dose of study intervention, except for the anti-EGFR containing regimen&#xD;
             including associated chemotherapy if applicable, which may be continued until&#xD;
             enrollment of the participant in the study&#xD;
&#xD;
          -  Any unresolved toxicity Grade 2 or more according to the National Cancer&#xD;
             Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0, from&#xD;
             previous anticancer therapy excluding neuropathy, alopecia and rash&#xD;
&#xD;
          -  Severe hypersensitivity reactions to monoclonal antibodies (Grade greater than or&#xD;
             equal to [&gt;=] 3 NCI-CTCAE v 5.0), any history of anaphylaxis, or uncontrolled asthma&#xD;
             (i.e., 3 or more occurrences of partially controlled asthma)&#xD;
&#xD;
          -  Discontinuation of the most recent cetuximab or panitumumab containing therapy due to&#xD;
             an adverse event&#xD;
&#xD;
          -  Prior treatment with other agents targeting the hepatocyte growth factor&#xD;
             (HGF)/Mesenchymal epithelial transition (MET) pathway&#xD;
&#xD;
          -  Impaired cardiac function: Left ventricular ejection fraction less than [&lt;] 45 percent&#xD;
             [%] defined by echocardiography (a screening assessment not required for participants&#xD;
             without a history of congestive heart failure unless clinically indicated); Serious&#xD;
             arrhythmia; Unstable angina pectoris; New York Heart Association heart failure Class&#xD;
             III and IV; Myocardial infarction within the last 12 months prior to study entry and&#xD;
             Symptomatic pericardial effusion; Corrected QT interval by Fridericia (QTcF) greater&#xD;
             than (&gt;) 480 milliseconds (ms)&#xD;
&#xD;
          -  Hypertension uncontrolled by standard therapies (not stabilized to less than [&lt;&#xD;
             ]150/90 millimeter of mercury [mmHg])&#xD;
&#xD;
          -  History of neoplasm other than mCRC&#xD;
&#xD;
          -  History of difficulty swallowing, malabsorption, or other chronic gastrointestinal&#xD;
             disease, or conditions that may hamper compliance and/or absorption of the test&#xD;
             products&#xD;
&#xD;
          -  Known infection with human immunodeficiency virus, or an active infection with&#xD;
             hepatitis B or hepatitis C virus&#xD;
&#xD;
          -  Major surgery within 28 days prior to Day 1 of study intervention&#xD;
&#xD;
          -  History of Interstitial lung disease (ILD) or interstitial pneumonitis including&#xD;
             radiation pneumonitis that required steroid treatment&#xD;
&#xD;
          -  Other protocol defined exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Medical Information</last_name>
    <phone>888-275-7376</phone>
    <email>eMediUSA@emdserono.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@emdgroup.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles (UCLA)</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgetown Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Hospital</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>322224-1865</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214-3728</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Shore-LIJ Monter Cancer Center</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Allegheny-Singer Research Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Vasicek Cancer Treatment Center</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aurora Cancer Care - Milwaukee West</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universtity Hospital Brno</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dept. of Oncology Faculty Hospital Motol</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Na Bulovce</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU BesanÃ§on HÃ´pital Jean Minjoz</name>
      <address>
        <city>Besancon Cedex</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of BesanÃ§on</name>
      <address>
        <city>BesanÃ§on</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont Ferrand Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU HÃ´pital Henri Mondor</name>
      <address>
        <city>CrÃ©teil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo</name>
      <address>
        <city>Le Mans Cedex 02</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Curie Institute</name>
      <address>
        <city>Saint Cloud</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Curie - RenÃ©-Huguenin Hospital</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura die Tumori</name>
      <address>
        <city>Meldona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS - Istituto Tumori Milano</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori, Fondazione G. Pascale Napoli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UOC Oncoematologia AOU Vanvitelli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto IRCCS</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana-Ospedale Santa Chiara</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Foundation IRCCS Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo FG</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arkangelsk Clinical Oncological Dyspensary</name>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kursk Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Kislino</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;National Medical Research Center of Oncology n.a. N.N. Blokhina&quot; of the MoH of the RF</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Limited Liability Company Medicine 24/7</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Russian Cancer research center n.a. N.N. Blokhin</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omsk Regional Oncology Dispensary</name>
      <address>
        <city>Omsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LLC Clinica UZI 4D</name>
      <address>
        <city>Pyatigorsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pavlov First Saint Petersburg State Medical University</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tomsk National Research Medical Center</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MKMC Medical City</name>
      <address>
        <city>Tyumen</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SAHI Republican Clinical Oncology Dispensary</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>VHIO Valle de Hebron Instituto de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H.U. Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HM-CIOCC</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Madrid Norte Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital UNiversitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H.U.MarquÃ©s de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HUVirgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Consorcio Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bristol Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beatson WJSCC</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guy's &amp; St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS202202_0002</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <link>
    <url>https://medical.emdserono.com/en_US/home.html</url>
    <description>US Medical Information website, Medical Resources</description>
  </link>
  <link>
    <url>https://www.clinicaltrials.targeting-met.com/en</url>
    <description>Targeting MET Clinical Trial Program</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2020</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>RAS wild-type</keyword>
  <keyword>Tepotinib</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>Erbitux</keyword>
  <keyword>Epidermal growth factor receptor resistance</keyword>
  <keyword>Hepatocyte growth factor</keyword>
  <keyword>Panitumumab</keyword>
  <keyword>Mesenchymal epithelial transition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Tepotinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and- development/healthcare/clinical-trials/commitment-responsible-data-sharing.html</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

